RBM5 and leukemia: Strikingly, RBM5 shRNA-treated animals exhibited much less splenomegaly and reduced leukemia cell infiltration in bone marrow, spleen, and peripheral blood compared to the wild-type control (Fig. 3f–h; Additional file 1: Fig. S3f).